provide JT with licenses to related technology. In return for these licenses, JT will pay Abgenix $10 million. JT also retains options to, or licenses on, several antigen targets it has previously nominated under the Xenotech structure. For all antibody products generated using XenoMouse technology and developed by JT, JT will make license fee payments to Abgenix as well as royalty payments on any product sales. "Including Japan Tobacco, we have 15 XenoMouse partners pursuing at least 20 product candidates, a number we expect to grow at an accelerating pace," Greer noted. "Japan Tobacco has been a tremendously supportive partner for us over the years, and we look forward to continuing to work with them under the new arrangement." A former subsidiary of JT America and Cell Genesys formed Xenotech, an equally owned limited partnership, in 1991. When Cell Genesys created Abgenix in 1996 as a wholly owned subsidiary, Cell Genesys assigned its interest in Xenotech to Abgenix. JT and its subsidiaries invested more than an estimated $40 million in the creation of XenoMouse technology. "Japan Tobacco is proud to have contributed to the creation of XenoMouse technology; however, our strategy regarding XenoMouse technology has evolved as our pharmaceutical business has grown," stated Mr. Takashi Kato, Managing Director, Pharmaceutical Division of JT. "Our emphasis now will be on generating antibody products for our pharmaceutical division to market itself rather than on creating a royalty based income stream." Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in huma
'"/>

Contact: Kurt Leutzinger, Abgenix, Inc.
510-608-6575
Porter Novelli
19-Dec-1999


Page: 1 2 3 4
Related biology news :

1. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
2. Abgenix initiates phase III clinical trial of graft versus host disease therapy
3. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. $18 million bioinformatics center to become weapon against deadly diseases
8. Biochemist becomes 15th UT Southwestern faculty member serving on National Academy of Sciences
9. Brain cells become more discriminating when they work together
10. How meals become bones
11. Adult mouse bone marrow stem cells can become cells of the nervous system